Posted by Dipali Harde
Filed in Other 14 views
Emergen Research has introduced a new and comprehensive collection of market research content, designed to help businesses better understand industry trends and make informed strategic decisions. This latest initiative reflects the company’s ongoing commitment to delivering practical insights that can be directly applied in real-world business scenarios.
The Insomnia Therapeutics market is expected to grow from an estimated USD 3.1 billion in 2024 to USD 4.8 billion in 2033, at a CAGR of 5.00%.
The global Insomnia Therapeutics market size is expected to grow from 3.1 billion by the end of 2024 to 4.8 billion by 2033, registering a revenue CAGR of 5.00% during the forecast period. The market for insomnia therapeutics has grown dramatically as the frequency of sleep problems globally has increased. Many businesses have introduced fresh goods and services, so driving up the market expansion.
For instance, according to a Translational and Clinical Pharmacology in 2024 article, Somryst, a digital prescription therapy smartphone app-based CBT-I, was licensed by the U.S. FDA in 2024 and showed significant results in patients with insomnia.
Furthermore included in the article were dual orexin receptor antagonists, which comprise daridorexant and suvorexant authorized by the U.S. Food and Drug Administration (U.S. FDA) as a new pharmacotherapeutic approach for insomnia.
Common pharmaceuticals, such as benzodiazepines and non-benzodiazepine sleep aids, are often used for temporary relief. Anxiety, sleeplessness, and seizures are common reasons for benzodiazepine prescriptions in the United States, but the drug comes with serious hazards, especially when used with opiates. Nearly 12.6 percent of American people reported taking benzodiazepines in 2023, with 2.1 percent admitting abuse.
Overcoming the risks of addiction and other negative side effects, scientists are looking for better and safer alternatives to these drugs. Due to their better safety profiles and action mechanisms, new medicines are gaining acceptance.
As of late, cognitive behavioral treatment for insomnia (CBT-I) has become more popular. Evidence-based cognitive behavioral therapy for insomnia (CBT-I) takes a methodical approach to treating the underlying mental health issues that contribute to sleep disturbances. Seventy to eighty percent of those suffering from chronic insomnia find relief with Cognitive Behavioral Therapy for Insomnia (CBT-I), according to research.
Having problems falling or staying asleep at least three times per week for three months or more is considered chronic insomnia, and it affects about 10-15% of individuals in the US. First-line treatment for persistent insomnia is cognitive behavioral therapy. Should CBT be ineffective, a pharmaceutical intervention is then available.
For example, Zydus got U.S. FDA approval for Triazolam, which is used to treat short-term basis insomnia, in December 2021. Under the Medicare Benefits Schedule (MBS) launched on January 1, 2022, the Australian government sponsored permanent telehealth arrangements.
It encourages safe and fair telehealth services and offers patient refunds for a wide spectrum of phone and video services by medical professionals. These elements have all encouraged insomnia treatments to develop; knowledge of this has also helped the industry explode in the projected timeframe.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-free-sample/4051
Market Segmentation:-
One of the most important aspects of this newly launched Insomnia Therapeutics market research content is its detailed segmentation of the market. Instead of presenting a general overview, the report breaks the market down into specific categories such as product types, applications, end-user industries, and regional performance. This structured approach allows businesses to identify exactly where opportunities lie and which segments are likely to experience significant growth. By understanding these variations, companies can focus their efforts more effectively and allocate resources where they are most needed.
The presence of global and regional players such as Takeda Pharmaceutical Company Ltd., Vanda Pharmaceuticals, Merck & Co., Inc., Pfizer Inc., and Teva Pharmaceutical Industries Ltd. are among the prominent companies in the Insomnia Therapeutics market. Significant market participants are investing substantial funds in research and development to improve their product offerings, hence facilitating further growth in the insomnia industry.
Significant market players are implementing several strategic efforts to broaden their global presence, including key developments such as new contractual agreements, product launches, mergers and acquisitions, enhanced investments, and collaborations with other entities. Insomnia industry competitors must provide economical products to thrive in a more competitive and expanding market landscape.
For instance, on August 8, 2024, Insomnia Therapeutics obtained FDA clearance for "SlumberX," a novel therapeutic intervention for insomnia. This medication seeks to provide a rapid-acting remedy with little adverse effects, representing a notable enhancement in its product range.
In addition to segmentation, the report is particularly valuable for a wide range of stakeholders. Investors looking for new opportunities, startups aiming to enter the market, and established enterprises seeking expansion strategies can all benefit from the insights provided. Even consulting firms, research organizations, and policymakers can use this information to support planning and decision-making processes.
The Insomnia Therapeutics market research content itself has been developed using a combination of advanced research methodologies and expert analysis. Emergen Research has ensured that the data is not only accurate but also relevant to current market conditions. The content includes detailed reports, case studies, whitepapers, and trend analyses, covering industries such as healthcare, technology, manufacturing, finance, and consumer goods. This wide coverage makes the research applicable to businesses operating in different sectors.
competitive landscape:-
Another key highlight of the report is the comprehensive analysis of the competitive landscape. Businesses today operate in an environment where competition is constantly evolving. Understanding what competitors are doing is crucial for staying ahead. The report provides detailed profiles of major companies in the global Insomnia Therapeutics market and outlines their strategies, recent developments, and market positioning. It also examines activities such as mergers and acquisitions, partnerships, product launches, and technological advancements, giving businesses a clear picture of the competitive environment.
The rising prevalence of insomnia and other sleep disorders is a significant driver of the insomnia treatments market expansion. Research indicates that a substantial proportion of individuals globally encounter sleep disturbances of varying severity.
The increased frequency of insomnia is caused in part by many factors, including stress, lifestyle changes, and undetected side effects of drugs. This phenomenon is best shown by the rise in sleep problems linked with modern high-stress levels and too much screen exposure.
Since persistent insomnia impairs overall health, cognitive function, and day-to-day activities, effective treatment alternatives are crucial. Pharmaceutical companies and research institutes are substantially investing in the development of new goods and treatments to meet the increasing demand. New pharmacological formulations, such as combination and extended-release medications, are being researched to improve safety and effectiveness.
The increasing comprehension of the impact of sleep problems on mental health and productivity is propelling the need for effective insomnia therapies. The market is growing as insomnia is getting more widespread, and both prescription and over-the-counter sleep medications are more needed.
The National Council on Aging claims that some insomnia affects more than thirty per cent of persons. By June 2024, 12% of Americans are expected to have been diagnosed with a chronic sleep issue, according to the American Academy of Sleep Medicine. Further market expansion is projected from the rising senior population, changing demand for treatment options, and expanding public knowledge of insomnia.
At its core, the purpose of this research content is to provide actionable insights rather than just raw data. Emergen Research focuses on helping businesses translate information into practical strategies. Whether it is identifying new customer segments, improving existing products, or entering new markets, the report offers guidance that can lead to measurable results. This approach makes the content especially valuable for organizations looking to grow in a structured and sustainable manner.
Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/4051
In today’s dynamic business environment, staying updated with the latest trends is essential. Markets are influenced by a variety of factors including technological advancements, economic conditions, and changing consumer behavior. Companies that fail to keep up with these changes risk falling behind their competitors. Emergen Research addresses this challenge by regularly updating its content to reflect the latest developments. This ensures that businesses always have access to current and relevant information.
Another important strength of the research is the inclusion of expert insights. The analysts behind this content bring years of industry experience and a deep understanding of market dynamics. Their perspectives help businesses not only understand what is happening in the market but also why it is happening. This deeper level of insight enables companies to make more confident and informed decisions.
Browse Full Report Description + Research Methodology + Table of Content + Infographics @ https://www.emergenresearch.com/industry-report/insomnia-therapeutics-market
Emergen Research has positioned itself as a reliable partner for businesses seeking high-quality market intelligence. The company’s focus on accuracy, clarity, and practical value sets it apart in the research industry. By offering a combination of detailed analysis, actionable recommendations, and expert insights, Emergen Research ensures that its clients are well-equipped to navigate complex market environments.
About Emergen Research
Emergen Research is a leading provider of market research and consulting services, offering syndicated reports, customized research solutions, and expert advisory services. The company helps clients understand market trends, analyze consumer behavior, and identify growth opportunities across various industries. With a strong emphasis on delivering fact-based and relevant insights, Emergen Research continues to support businesses in making smarter and more strategic decisions.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: https://www.emergenresearch.com/
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
